Tom Powles/X
Jun 5, 2025, 04:52
Tom Powles: Promising Data on Carboplatin/Gemcitabine in M1 Bladder Cancer from EVP
Tom Powles, Professor at the University of London, shared a post on X:
“The most robust data post EVP in M1 bladder cancer by Michal Sternschuss Carboplatin/gem was the commonest regimen.
Results showed higher RRs than expected (50%) PFS =4.5 months & OS =11 months are good. 1st line gem/carbo OS was ~10 months
previously?”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 07:59
Aug 8, 2025, 05:47
Aug 8, 2025, 05:01